1996
DOI: 10.1111/j.1432-1033.1996.0164n.x
|View full text |Cite
|
Sign up to set email alerts
|

Dissociation Kinetics of Actinomycin D from Individual GpC Sites in DNA

Abstract: We have examined the kinetics of dissociation of actinomycin from GpC sites in several DNA fragments containing synthetic DNA inserts, by a variation of the footprinting technique. Complexes of the ligand with radiolabelled DNA fragments were dissociated by adding a large excess of unlabelled calf thymus DNA. Samples were removed from this mixture at subsequent time intervals and subjected to DNase I footprinting. The rate of disappearance of the footprints varied considerably between the GpC sites located in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1997
1997
2020
2020

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 10 publications
(1 citation statement)
references
References 36 publications
(12 reference statements)
0
1
0
Order By: Relevance
“…[32][33] Actinomycin D intercalates its chromophore between 5 0 -GC-3 0 DNA base pairs, [34] yet not all the 5 0 -GC-3 0 sites are equivalent targets for this compound. [35] Actinomycin D antitumor activity is related to its capacity for inhibiting RNA polymerases and decrease transcription. It is used as a tool for producing rapid and specific inhibition of RNA synthesis in studies on the metabolism of messenger RNA.…”
Section: Anthracyclines and Bisanthracyclinesmentioning
confidence: 99%
“…[32][33] Actinomycin D intercalates its chromophore between 5 0 -GC-3 0 DNA base pairs, [34] yet not all the 5 0 -GC-3 0 sites are equivalent targets for this compound. [35] Actinomycin D antitumor activity is related to its capacity for inhibiting RNA polymerases and decrease transcription. It is used as a tool for producing rapid and specific inhibition of RNA synthesis in studies on the metabolism of messenger RNA.…”
Section: Anthracyclines and Bisanthracyclinesmentioning
confidence: 99%